MED29

Summary

MED29 (mediator complex subunit 29, HGNC:23074) is a protein-coding gene on chromosome 19q13.2, encoding Mediator of RNA polymerase II transcription subunit 29 (Q9NX70). Component of the Mediator complex, a coactivator involved in the regulated transcription of nearly all RNA polymerase II-dependent genes. It is a common-essential gene (DepMap: required in 96.0% of cancer cell lines).

MED29 is a subunit of the Mediator complex, a multiprotein coactivator of RNA transcription that interacts with DNA-bound transcriptional activators, RNA polymerase II (see MIM 180660), and general initiation factors (Sato et al., 2003 [PubMed 14576168]).

Source: NCBI Gene 55588 — RefSeq curated summary.

At a glance

• Clinical variants (ClinVar): 33 total — 1 pathogenic
• Cancer dependency (DepMap): dependent in 96.0% of screened cell lines (common-essential)
• MANE Select transcript: NM_017592

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:23074
Approved symbol	MED29
Name	mediator complex subunit 29
Location	19q13.2
Locus type	gene with protein product
Status	Approved
Aliases	DKFZp434H247, MED2
Ensembl gene	ENSG00000063322
Ensembl biotype	protein_coding
OMIM	612914
Entrez	55588

Gene structure

Transcript identifiers

Ensembl transcripts: 8 — 6 protein_coding, 2 nonsense_mediated_decay

ENST00000315588, ENST00000594368, ENST00000596297, ENST00000599417, ENST00000600973, ENST00000615911, ENST00000865179, ENST00000865180

RefSeq mRNA: 2 — MANE Select: NM_017592 NM_001317770, NM_017592

CCDS: CCDS33021, CCDS92614

Canonical transcript exons

ENST00000315588 — 4 exons

Exon	Start	End
ENSE00000341727	39392464	39392522
ENSE00001051868	39391378	39391638
ENSE00001423955	39397457	39400641
ENSE00003523402	39393553	39393637

Expression profiles

Bgee: expression breadth ubiquitous, 252 present calls, max score 93.79.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 59.4007 / max 536.7557, expressed in 1822 samples.

FANTOM5 promoters (4 alternative TSS)

Promoter ID	TPM avg	Samples expressed
175702	58.8035	1822
175705	0.3253	79
175701	0.1696	61
175704	0.1023	45

Top tissues by expression

257 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
prefrontal cortex	UBERON:0000451	93.79	gold quality
amygdala	UBERON:0001876	93.75	gold quality
anterior cingulate cortex	UBERON:0009835	93.47	gold quality
putamen	UBERON:0001874	93.37	gold quality
nucleus accumbens	UBERON:0001882	93.26	gold quality
caudate nucleus	UBERON:0001873	92.99	gold quality
hypothalamus	UBERON:0001898	92.86	gold quality
C1 segment of cervical spinal cord	UBERON:0006469	92.74	gold quality
hindlimb stylopod muscle	UBERON:0004252	92.63	gold quality
right frontal lobe	UBERON:0002810	92.62	gold quality
spinal cord	UBERON:0002240	92.47	gold quality
substantia nigra	UBERON:0002038	92.42	gold quality
medial globus pallidus	UBERON:0002477	92.20	gold quality
frontal cortex	UBERON:0001870	92.16	gold quality
neocortex	UBERON:0001950	92.02	gold quality
dorsolateral prefrontal cortex	UBERON:0009834	91.95	gold quality
midbrain	UBERON:0001891	91.89	gold quality
Brodmann (1909) area 9	UBERON:0013540	91.81	gold quality
forebrain	UBERON:0001890	91.51	gold quality
globus pallidus	UBERON:0001875	91.50	gold quality
cerebral cortex	UBERON:0000956	91.30	gold quality
Ammon’s horn	UBERON:0001954	91.12	gold quality
brain	UBERON:0000955	91.10	gold quality
temporal lobe	UBERON:0001871	91.01	gold quality
lateral globus pallidus	UBERON:0002476	90.44	gold quality
gastrocnemius	UBERON:0001388	90.41	gold quality
stromal cell of endometrium	CL:0002255	90.36	gold quality
muscle of leg	UBERON:0001383	90.04	gold quality
left adrenal gland	UBERON:0001234	89.98	gold quality
left adrenal gland cortex	UBERON:0035825	89.98	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	9.30

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): NR1I2

miRNA regulators (miRDB)

116 targeting MED29, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-6867-5P	100.00	82.21	3464
HSA-MIR-4425	100.00	67.59	1049
HSA-MIR-3064-3P	100.00	70.09	1254
HSA-MIR-4283	100.00	66.42	2097
HSA-MIR-6870-5P	99.99	68.55	2115
HSA-MIR-4650-5P	99.98	64.69	999
HSA-MIR-1229-3P	99.97	66.49	906
HSA-MIR-4723-5P	99.97	68.70	2034
HSA-MIR-5698	99.97	68.49	2029
HSA-MIR-7111-5P	99.97	68.48	2062
HSA-MIR-6825-5P	99.96	69.81	3431
HSA-MIR-559	99.95	72.28	3609
HSA-MIR-548AB	99.95	71.31	3488
HSA-MIR-9983-3P	99.94	71.48	3631
HSA-MIR-548A-5P	99.94	71.27	3482
HSA-MIR-548AD-5P	99.94	71.23	3502
HSA-MIR-548AE-5P	99.94	71.23	3502
HSA-MIR-548AK	99.94	71.24	3488
HSA-MIR-548AM-5P	99.94	71.24	3488
HSA-MIR-548AP-5P	99.94	71.14	3489
HSA-MIR-548AQ-5P	99.94	71.34	3426
HSA-MIR-548AR-5P	99.94	71.28	3515
HSA-MIR-548AS-5P	99.94	71.22	3482
HSA-MIR-548AU-5P	99.94	71.24	3488
HSA-MIR-548AY-5P	99.94	71.23	3502
HSA-MIR-548B-5P	99.94	71.23	3502
HSA-MIR-548BB-5P	99.94	71.27	3509
HSA-MIR-548C-5P	99.94	71.24	3488
HSA-MIR-548D-5P	99.94	71.23	3502
HSA-MIR-548H-5P	99.94	71.24	3488

Functional genomics

DepMap (CRISPR cell-line fitness): dependent in 96.0% of screened cell lines, common-essential.

Literature-anchored findings (GeneRIF, showing 6)

• A mammalian homolog of Drosophila melanogaster transcriptional coactivator intersex is a subunit of the mammalian Mediator complex (PMID:14576168)
• IXL is a subunit of the mammalian Mediator complex. (PMID:14576168)
• IXL is a subunit of the mammalian Mediator complex. (PMID:15175163)
• Overexpression of IXL in COS-7 cells inhibits the transcriptional activities of SRE and AP-1, suggesting that the IXL protein may act as a transcriptional suppressor in mitogen-activated protein kinase signaling pathway to mediate cellular functions. (PMID:15555573)
• IXL is required for cancer cell survival in 19q13-amplified tumors. (PMID:17332321)
• CHRDL1 inhibits OSCC metastasis via MAPK signaling-mediated inhibition of MED29. (PMID:39462350)

Cross-species orthologs

1 orthologs

Organism	Symbol	Gene ID
mus_musculus	Med29	ENSMUSG00000003444

Protein

Protein identifiers

Mediator of RNA polymerase II transcription subunit 29 — Q9NX70 (reviewed: Q9NX70)

Alternative names: Intersex-like protein, Mediator complex subunit 29

All UniProt accessions (5): Q9NX70, B4DUA7, M0R0A0, M0R0U2, M0R3F3

UniProt curated annotations — full annotation on UniProt →

Function. Component of the Mediator complex, a coactivator involved in the regulated transcription of nearly all RNA polymerase II-dependent genes. Mediator functions as a bridge to convey information from gene-specific regulatory proteins to the basal RNA polymerase II transcription machinery. Mediator is recruited to promoters by direct interactions with regulatory proteins and serves as a scaffold for the assembly of a functional preinitiation complex with RNA polymerase II and the general transcription factors.

Subunit / interactions. Component of the Mediator complex, which is composed of MED1, MED4, MED6, MED7, MED8, MED9, MED10, MED11, MED12, MED13, MED13L, MED14, MED15, MED16, MED17, MED18, MED19, MED20, MED21, MED22, MED23, MED24, MED25, MED26, MED27, MED29, MED30, MED31, CCNC, CDK8 and CDC2L6/CDK11. The MED12, MED13, CCNC and CDK8 subunits form a distinct module termed the CDK8 module. Mediator containing the CDK8 module is less active than Mediator lacking this module in supporting transcriptional activation. Individual preparations of the Mediator complex lacking one or more distinct subunits have been variously termed ARC, CRSP, DRIP, PC2, SMCC and TRAP. Associates with the MED18/MED20 heteromer.

Subcellular location. Nucleus.

Tissue specificity. Widely expressed in embryo and adult.

Similarity. Belongs to the Mediator complex subunit 29 family.

Isoforms (2)

UniProt ID	Names	Canonical?
Q9NX70-1	1	yes
Q9NX70-2	2

RefSeq proteins (2): NP_001304699, NP_060062* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR021018	Mediator_Med29_met	Family

Pfam: PF11568

UniProt features (11 total): helix 3, compositionally biased region 2, splice variant 2, initiator methionine 1, chain 1, region of interest 1, modified residue 1

Structure

Experimental structures (PDB)

10 structures.

PDB	Method	Resolution (Å)
7EMF	ELECTRON MICROSCOPY	3.5
8TRH	ELECTRON MICROSCOPY	3.7
7ENA	ELECTRON MICROSCOPY	4.07
7ENC	ELECTRON MICROSCOPY	4.13
8GXS	ELECTRON MICROSCOPY	4.16
7ENJ	ELECTRON MICROSCOPY	4.4
8T9D	ELECTRON MICROSCOPY	4.66
7LBM	ELECTRON MICROSCOPY	4.8
8GXQ	ELECTRON MICROSCOPY	5.04
8TQW	ELECTRON MICROSCOPY	8.2

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q9NX70-F1	73.96	0.37

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (1): 2

Function

Pathways and Gene Ontology

Reactome pathways

12 pathways

ID	Pathway
R-HSA-1989781	PPARA activates gene expression
R-HSA-381340	Transcriptional regulation of white adipocyte differentiation
R-HSA-9833110	RSV-host interactions
R-HSA-1266738	Developmental Biology
R-HSA-1430728	Metabolism
R-HSA-1643685	Disease
R-HSA-400206	Regulation of lipid metabolism by PPARalpha
R-HSA-556833	Metabolism of lipids
R-HSA-5663205	Infectious disease
R-HSA-9820952	Respiratory Syncytial Virus Infection Pathway
R-HSA-9824446	Viral Infection Pathways
R-HSA-9843745	Adipogenesis

MSigDB gene sets: 127 (showing top): REACTOME_TRANSCRIPTIONAL_REGULATION_OF_WHITE_ADIPOCYTE_DIFFERENTIATION, GOBP_POSITIVE_REGULATION_OF_DNA_TEMPLATED_TRANSCRIPTION_INITIATION, MODULE_308, CAGCAGG_MIR370, GOBP_REGULATION_OF_DNA_TEMPLATED_TRANSCRIPTION_INITIATION, MODULE_301, GOBP_DNA_TEMPLATED_TRANSCRIPTION_INITIATION, GOBP_TRANSCRIPTION_INITIATION_AT_RNA_POLYMERASE_II_PROMOTER, KUUSELO_PANCREATIC_CANCER_19Q13_AMPLIFICATION, GOBP_PROTEIN_DNA_COMPLEX_ORGANIZATION, MODULE_188, GOBP_POSITIVE_REGULATION_OF_DNA_TEMPLATED_TRANSCRIPTION_ELONGATION, RODRIGUES_THYROID_CARCINOMA_POORLY_DIFFERENTIATED_DN, GOBP_REGULATION_OF_DNA_TEMPLATED_TRANSCRIPTION_ELONGATION, GOCC_RNA_POLYMERASE_II_TRANSCRIPTION_REGULATOR_COMPLEX

GO Biological Process (4): regulation of transcription by RNA polymerase II (GO:0006357), positive regulation of transcription elongation by RNA polymerase II (GO:0032968), RNA polymerase II preinitiation complex assembly (GO:0051123), positive regulation of transcription initiation by RNA polymerase II (GO:0060261)

GO Molecular Function (2): transcription coregulator activity (GO:0003712), protein binding (GO:0005515)

GO Cellular Component (4): nucleus (GO:0005634), nucleoplasm (GO:0005654), mediator complex (GO:0016592), core mediator complex (GO:0070847)

Reactome top-level categories

Rollup of top-9 pathways:

Category	Pathways
Regulation of lipid metabolism by PPARalpha	1
Adipogenesis	1
Respiratory Syncytial Virus Infection Pathway	1
Metabolism of lipids	1
Metabolism	1
Disease	1
Viral Infection Pathways	1
Infectious disease	1
Developmental Biology	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
positive regulation of transcription by RNA polymerase II	2
transcription initiation at RNA polymerase II promoter	2
regulation of DNA-templated transcription	1
transcription by RNA polymerase II	1
transcription elongation by RNA polymerase II	1
positive regulation of DNA-templated transcription, elongation	1
regulation of transcription elongation by RNA polymerase II	1
transcription preinitiation complex assembly	1
regulation of transcription initiation by RNA polymerase II	1
positive regulation of DNA-templated transcription initiation	1
transcription regulator activity	1
binding	1
intracellular membrane-bounded organelle	1
nuclear lumen	1
cellular anatomical structure	1
core mediator complex	1
nuclear protein-containing complex	1
RNA polymerase II transcription regulator complex	1

Protein interactions and networks

STRING

902 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
MED29	MED27	Q6P2C8	994
MED29	MED18	Q9BUE0	979
MED29	MED20	Q9H944	977
MED29	MED15	Q96RN5	952
MED29	MED16	Q9Y2X0	932
MED29	MED24	O75448	875
MED29	MED14	O60244	850
MED29	MED17	Q9NVC6	841
MED29	MED7	O43513	832
MED29	MED21	Q13503	828
MED29	MED11	Q9P086	819
MED29	MED6	O75586	818
MED29	MED22	Q15528	790
MED29	MED8	Q96G25	785
MED29	MED30	Q96HR3	772

IntAct

166 interactions, top by confidence:

A	B	Type	Score
MED10	MED19	psi-mi:“MI:0914”(association)	0.910
MED10	MED19	psi-mi:“MI:0915”(physical association)	0.910
MED4	MED19	psi-mi:“MI:0914”(association)	0.900
CDK8	MED14	psi-mi:“MI:0914”(association)	0.900
MED29	MED19	psi-mi:“MI:0914”(association)	0.890
MED29	MED18	psi-mi:“MI:0914”(association)	0.890
MED29	MED18	psi-mi:“MI:0915”(physical association)	0.890
MED19	MED29	psi-mi:“MI:0915”(physical association)	0.890
MED21	MED19	psi-mi:“MI:0914”(association)	0.880
MED10	MED6	psi-mi:“MI:0914”(association)	0.870
CDK8	MED19	psi-mi:“MI:2364”(proximity)	0.850
CDK8	MED19	psi-mi:“MI:0914”(association)	0.850
MED20	MED29	psi-mi:“MI:0915”(physical association)	0.850
MED29	MED20	psi-mi:“MI:0915”(physical association)	0.850

BioGRID (341): MED29 (Affinity Capture-RNA), MED29 (Affinity Capture-RNA), MED29 (Affinity Capture-MS), MED29 (Affinity Capture-MS), MED29 (Affinity Capture-MS), MED29 (Affinity Capture-MS), MED29 (Affinity Capture-MS), MED29 (Affinity Capture-MS), MED29 (Affinity Capture-MS), MED1 (Co-fractionation), MED10 (Co-fractionation), MED11 (Co-fractionation), MED14 (Co-fractionation), MED15 (Co-fractionation), MED16 (Co-fractionation)

ESM2 similar proteins: A1A4Q8, A2RSY1, A4IHD9, A4IIZ9, A8E5U3, B5DF93, F4HPA7, O57595, P68943, Q03297, Q08BU1, Q08D01, Q0IHI6, Q24767, Q2QCI8, Q2TBN4, Q2YDF2, Q3TC46, Q499B3, Q4VCS5, Q5HZZ6, Q5PPY2, Q5R8Q4, Q5RBZ4, Q5RKN3, Q60520, Q62415, Q66KX4, Q6DD30, Q6GP15, Q6NYT1, Q6PC45, Q6PEH8, Q71SY5, Q7KW14, Q86TB9, Q8BG30, Q8JHI6, Q8VCB2, Q8VHG2

Diamond homologs: A1A4Q8, Q08D01, Q16TJ7, Q5ISW3, Q5ISW5, Q5RBZ4, Q66KX4, Q7KBL8, Q7PUD7, Q8JHI6, Q9DB91, Q9NX70

SIGNOR signaling

1 interactions.

A	Effect	B	Mechanism
MED29	“form complex”	“Core mediator complex”	binding

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 87 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
Respiratory Syncytial Virus Infection Pathway	25	78.1×	8e-41
RSV-host interactions	25	62.1×	3e-38
Adipogenesis	25	62.1×	3e-38
Regulation of lipid metabolism by PPARalpha	25	56.0×	5e-37
Transcriptional regulation of white adipocyte differentiation	25	51.5×	5e-36
Epigenetic regulation of adipogenesis genes by MLL3 and MLL4 complexes	15	51.3×	5e-21
Epigenetic regulation of gene expression by MLL3 and MLL4 complexes	15	46.9×	2e-20
PPARA activates gene expression	25	37.5×	3e-32

GO biological processes:

GO term	Partners	Fold	FDR
positive regulation of transcription elongation by RNA polymerase II	21	84.3×	5e-34
positive regulation of transcription initiation by RNA polymerase II	22	79.7×	8e-35
RNA polymerase II preinitiation complex assembly	21	76.1×	5e-33
transcription initiation at RNA polymerase II promoter	8	40.0×	2e-09
somatic stem cell population maintenance	11	36.4×	9e-13
transcription by RNA polymerase II	9	8.5×	7e-05
protein ubiquitination	12	6.6×	2e-05

Disease & clinical

Clinical variants and AI predictions

ClinVar

33 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	1
Likely pathogenic	0
Uncertain significance	25
Likely benign	4
Benign	0

Top pathogenic / likely-pathogenic (1)

Variant ID	HGVS	Classification
3778699	NM_017592.4(MED29):c.353T>C (p.Leu118Pro)	Pathogenic

SpliceAI

612 predictions. Top by Δscore:

Variant	Effect	Δscore
19:39391628:A:T	donor_gain	1.0000
19:39392523:G:GG	donor_gain	1.0000
19:39393550:TAG:T	acceptor_loss	1.0000
19:39393551:A:AG	acceptor_gain	1.0000
19:39393552:G:GC	acceptor_gain	1.0000
19:39393552:GA:G	acceptor_gain	1.0000
19:39393552:GAA:G	acceptor_gain	1.0000
19:39393552:GAAA:G	acceptor_gain	1.0000
19:39393633:GCCTG:G	donor_gain	1.0000
19:39393636:TGGTA:T	donor_loss	1.0000
19:39393639:T:G	donor_loss	1.0000
19:39391634:TACAG:T	donor_loss	0.9900
19:39391635:ACAG:A	donor_loss	0.9900
19:39391636:CAG:C	donor_loss	0.9900
19:39391637:AG:A	donor_loss	0.9900
19:39391638:GG:G	donor_loss	0.9900
19:39391640:T:G	donor_loss	0.9900
19:39391646:GCCT:G	donor_gain	0.9900
19:39391678:T:TA	donor_gain	0.9900
19:39391679:A:AA	donor_gain	0.9900
19:39393638:G:GG	donor_gain	0.9900
19:39397455:A:AG	acceptor_gain	0.9900
19:39397456:G:GA	acceptor_gain	0.9900
19:39397456:GC:G	acceptor_gain	0.9900
19:39397456:GCGC:G	acceptor_gain	0.9900
19:39393544:T:TA	acceptor_gain	0.9800
19:39397657:C:T	donor_gain	0.9800
19:39392518:GGACA:G	donor_gain	0.9700
19:39392519:GACAG:G	donor_gain	0.9700
19:39393548:T:TA	acceptor_gain	0.9700

AlphaMissense

1292 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
19:39391610:T:C	L63P	1.000
19:39391622:T:C	L67P	1.000
19:39391634:T:C	L71P	1.000
19:39392479:G:C	A78P	1.000
19:39392480:C:A	A78E	1.000
19:39393594:T:C	L106P	1.000
19:39393597:A:T	E107V	1.000
19:39393598:A:C	E107D	1.000
19:39393598:A:T	E107D	1.000
19:39393603:T:C	F109S	1.000
19:39393615:G:A	C113Y	1.000
19:39393616:T:G	C113W	1.000
19:39393618:A:C	D114A	1.000
19:39393618:A:G	D114G	1.000
19:39393618:A:T	D114V	1.000
19:39393621:A:C	Q115P	1.000
19:39393624:T:C	L116P	1.000
19:39393630:T:C	L118P	1.000
19:39393636:T:C	L120P	1.000
19:39397461:T:C	L122P	1.000
19:39397463:G:C	A123P	1.000
19:39397566:A:G	Y157C	1.000
19:39397574:T:G	Y160D	1.000
19:39397575:A:G	Y160C	1.000
19:39397608:C:A	A171D	1.000
19:39397629:T:C	L178P	1.000
19:39391605:G:C	K61N	0.999
19:39391605:G:T	K61N	0.999
19:39391622:T:G	L67R	0.999
19:39392468:T:G	L74W	0.999

dbSNP variants (sampled 300 via entrez): RS1000051764 (19:39395106 A>G), RS1000124844 (19:39395301 A>C), RS1000218792 (19:39398768 A>G), RS1000670012 (19:39393855 C>T), RS1000824330 (19:39399993 A>G), RS1001170581 (19:39399408 C>A), RS1001171467 (19:39399742 C>T), RS1001215456 (19:39392816 A>G), RS1001838590 (19:39391398 A>C,G,T), RS1002062494 (19:39398405 G>A), RS1002137511 (19:39398687 C>T), RS1002164306 (19:39394550 C>T), RS1002312358 (19:39391704 A>G,T), RS1002325639 (19:39400371 G>GT), RS1003016887 (19:39390050 T>C)

Disease associations

OMIM: gene MIM:612914 | disease phenotypes:

GenCC curated gene-disease

Mondo (1): breast ductal adenocarcinoma (MONDO:0005590)

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

0 associations (top):

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D018270	Carcinoma, Ductal, Breast	C04.557.470.200.025.232.500; C04.557.470.615.132.500; C04.588.180.390; C17.800.090.500.390

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

24 total (human), top 24 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
aristolochic acid I	increases expression	1
alpha phellandrene	decreases expression	1
alpha-pinene	affects cotreatment, increases oxidation, increases abundance	1
methacrylaldehyde	increases oxidation, increases abundance, affects cotreatment	1
diallyl trisulfide	increases expression	1
CGP 52608	affects binding, increases reaction	1
2-palmitoylglycerol	increases expression	1
ICG 001	increases expression	1
abrine	decreases expression	1
PCI 5002	affects cotreatment, increases expression	1
4-(4-((5-(4,5-dimethyl-2-nitrophenyl)-2-furanyl)methylene)-4,5-dihydro-3-methyl-5-oxo-1H-pyrazol-1-yl)benzoic acid	increases expression	1
Acetaminophen	increases expression	1
Acrolein	increases abundance, affects cotreatment, increases oxidation	1
Air Pollutants	affects cotreatment, increases abundance, increases oxidation	1
Atrazine	decreases expression	1
Benzo(a)pyrene	increases methylation	1
Ozone	increases oxidation, increases abundance, affects cotreatment	1
Smoke	decreases expression	1
Tunicamycin	increases expression	1
Vincristine	decreases expression	1
Zinc	affects cotreatment, increases expression	1
Aflatoxin B1	increases methylation	1
Okadaic Acid	increases expression	1
Volatile Organic Compounds	affects cotreatment, increases oxidation	1

Clinical trials (associated diseases)

11 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT03414970	PHASE3	ACTIVE_NOT_RECRUITING	Hypofractionated Radiation Therapy After Mastectomy in Preventing Recurrence in Patients With Stage IIa-IIIa Breast Cancer
NCT00461344	PHASE2	TERMINATED	Docetaxel + Doxorubicin as Neoadjuvant Chemotherapy in Patients With Breast Cancer
NCT07499999	PHASE2	NOT_YET_RECRUITING	Randomized Double-Blind Phase II Trial of Baby Exemestane Versus Baby Tamoxifen in Post-Menopausal Women at High Risk for Breast Cancer
NCT00637364	PHASE1/PHASE2	SUSPENDED	High Intensity Focused Ultrasound Tumor Treatment for Pancreatic Cancer Pain
NCT02779855	PHASE1/PHASE2	COMPLETED	Talimogene Laherparepvec in Combination With Neoadjuvant Chemotherapy in Triple Negative Breast Cancer
NCT01753908	EARLY_PHASE1	COMPLETED	Broccoli Sprout Extract in Treating Patients With Breast Cancer
NCT01796041	EARLY_PHASE1	COMPLETED	Intraoperative Imaging of Breast Cancer With Indocyanine Green
NCT01208974	Not specified	ACTIVE_NOT_RECRUITING	Nipple-Areola Complex (NAC) Irradiation After Nipple-Sparing Mastectomy and Reconstruction
NCT01875198	Not specified	TERMINATED	Oncologic Impact of Splenectomy-omitting Radical Pancreatectomy in Well-selected Left-sided Pancreatic Cancer
NCT03543397	Not specified	UNKNOWN	MRI in Ductal Carcinoma in Situ (DCIS)
NCT03834532	Not specified	COMPLETED	Living Well After Breast Surgery